Cellivery Signs Comprehensive Collaboration Agreement with German Global Pharma Company for Platform Technology and Candidate Substance L/O

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 17th that it has signed a comprehensive Research Collaboration Agreement (RCA) for platform technology and new drug candidate licensing business with a Germany-based global pharmaceutical company with which it had been exploring the possibility of joint new drug research and development.

This pharmaceutical company is a global big pharma headquartered in Germany with more than 50,000 employees worldwide. This is the first contract with Cellivery. According to the company, the business meeting request was made at the partnering conference "Bio-Europe" held in Vienna, Austria, in March last year.

The global pharmaceutical company requested the research collaboration agreement (RCA) with the purpose of applying the TSDT platform core technology to its established cell-permeability evaluation system (CPES) to verify the types of pharmacological substances and target diseases. Through this contract, the pharmaceutical company will quantitatively analyze how much pharmacological substances enter target cells using the TSDT platform. Additionally, to determine the impact of the size and type of drugs to be delivered on delivery efficiency, multiple studies will be conducted by varying the types and sizes of various pharmacological substances such as proteins, peptides, nucleic acids, and antibodies.

A company official stated, "The global pharmaceutical company has shown interest and enthusiasm for our technology to the extent that they have independently built a new analysis system (CPES) over the past six months," adding, "This contract is the first one with a long-term partnership in mind, and after in-depth verification and analysis of the TSDT platform technology, they want to license the technology and apply it to disease areas where the best outcomes can be achieved."

Separately from this contract, Cellivery is continuing negotiations for a technology licensing agreement with another division of this pharmaceutical company for the development of cell-permeable nucleic acid therapeutics siRNA. According to the company, this division aims to develop and license a new 'peptide-nucleic acid therapeutic new drug' by chemically conjugating siRNA nucleic acid therapeutics, which have therapeutic efficacy for indications undisclosed by the company, to Cellivery’s cell membrane-permeable peptide aMTD. A company official added, "We cannot disclose detailed information, but negotiations are currently underway including specific amounts."

Although siRNA requires integration with delivery technologies like aMTD, global pharmaceutical companies are rushing into research and development because siRNA can effectively control the expression of virtually all genes. They are striving to secure technology that can deliver this unstable double-stranded RNA into the tissues and cells where lesions occur. In 2018, the siRNA therapeutic for transthyretin (hATTR) amyloidosis developed by Alnylam Pharmaceuticals in the United States was the first to receive FDA approval.

Cellivery CEO Daewoong Cho said, "We are very pleased to meet new business partners in addition to multiple collaborations such as joint research, joint development, verification contracts, and cooperation agreements currently underway with global pharmaceutical companies," adding, "Through this comprehensive research collaboration agreement for a long-term partnership, Cellivery has established new drug development research collaboration partnerships with four pharmaceutical companies ranked within the top 20 worldwide and is conducting various businesses."

This content was produced with the assistance of AI translation services.